- April 28th, 2022
Radiomics Sustainability Policy
Radiomics is pleased to share its sustainability policy, the measures in place and the actions we plan to take to make a positive impact on the environment around us.
- April 21st, 2022
The clinical needs and regulatory requirements of an imaging-based companion diagnostic
The fourth part in the series of articles about imaging-based companion diagnostics will focus on the necessary regulations and considerations and is available to read here.
- March 22nd, 2022
Technical considerations for an imaging-based companion diagnostic
The third part in the series of articles about imaging-based companion diagnostics will focus on their integration into clinics and is available to read here.
- March 15th, 2022
Radiomics is officially ISO 13485 certified
Radiomics is pleased to announce its Quality Management System has been certified to be fully compliant with EN ISO 13485:2016 Medical Devices – Quality Management Systems – Requirements for regulatory purposes) standard by the notified body IMQ.
- February 16th, 2022
9 in 10 pivotal clinical trials in oncology fail: Radiomics can help to make the best use of research investments
A recent review showed that 9 out of 10 clinical trials fail to test the therapy as effective, this begs the question if all potential insights from early-stage testing are being captured and used to guide the success in late-stage research and clinical use?
- December 13th, 2021
Developing an imaging-based companion diagnostic tool with Radiomics
The second part in the series of articles about imaging-based companion diagnostics will focus on their development and is available to read here.
- December 1st, 2021
Radiomics joins the FNIH Biomarkers Consortium
Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).
- November 25th, 2021
Radiomics announces the strategic support of OncoDNA in its prospective clinical trial SALMON
The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology
- November 17th, 2021
Radiomics secures €6 Million to fund new projects and initiatives
Radiomics announced that it has secured €6 Million in a pre-series B funding led by its main investors (Epimede and Noshaq) and backed by its original funders, its management team, some banks and non-dilutive financing from Walloon Regional Authorities in support of R&D Projects.
- November 9th, 2021
Kazia Therapeutics and Radiomics collaborate in development of novel therapy
Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.
- November 4th, 2021
What is an Imaging-based Companion Diagnostics and why is it needed?
Radiomics has produced a series of articles aimed at providing a complete overview of imaging companion diagnostics and their development pathway. The first one has now been released and is available by dropping an email to [email protected]
- August 24th, 2021
First distributed learning network machines for DRAGON installed
Radiomics installed in CHU Liege and University of Florence the first machines required for the connection to the distributed learning network in the framework of DRAGON. This project, funded by the European Commission’s Horizon 2020 program Innovative Medicine Initiative (IMI) aimed at using artificial intelligence (AI) and machine learning to develop decision support systems capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.
- May 19th, 2021
Visite de Mathieu Michel, Secrétaire d’Etat à la Digitalisation
La société Radiomics est heureuse et fière d’annoncer la visite, ce 19 mai 2021, de Monsieur Mathieu Michel, Secrétaire d’Etat fédéral belge à la Digitalisation, chargé de la Simplification administrative, de la Protection de la vie privée et de la Régie des Bâtiments.
- May 3rd, 2021
Radiomics Opens its first North American office in Toronto, Ontario
Radiomics is pleased to announce the official opening of its first North American sales and support office with the support of the Walloon investment support agency AWEX. The new office, established in Toronto, Ontario will kick-start the company's partnerships in the area, better accommodating pharma companies and clinicians’ needs through North America-based team members.
- April 20th, 2021
Radiomics CEO Wim Vos guest at Tekna Talks
Wim Vos CEO of Radiomics guest at Tekna Talks: Drug discovery – from airflow around a bobsleigh to airflow in the lungs.
- March 22nd, 2021
TIGER Consortium awarded EU Commission grant of EUR 6.9 million
The TIGER consortium led by eTheRNA immunotherapies and including Radiomics, is awarded an EU Commission’s grant for an HPV 16+ vaccine clinical trial
- March 2nd, 2021
DRAGON: la IA contro il COVID-19
L’Europa ha lanciato un nuovo progetto chiamato Dragon, per applicare l’intelligenza artificiale alla battaglia contro il COVID-19.
- February 22nd, 2021
Artificial intelligence helps doctors address inner ear problems
A new method to map the inner ear using artificial intelligence (AI). That is what the Belgian start-up Radiomics has developed in close collaboration with doctors and scientists from Maastricht UMC +, Maastricht University, Antwerp University Hospital (UZA) and the University of Antwerp.
- February 18th, 2021
AI tool for the segmentation of the inner ear on MRI
Radiomics together with UZAntwerpen and UMaastricht, has developed a novel tool for the automatic identification of the inner ear on MRI
- January 26th, 2021
OncoRadiomics becomes Radiomics
With great enthusiasm and pride, the OncoRadiomics team today unveils the company's new brand identity: ‘Radiomics’.
- January 26th, 2021
Radiomics un nouveau nom et des objectifs de croissance
OncoRadiomics, spin-off de l’Université de Maastricht installée à Liège et spécialisée dans le développement d’outils innovants de radiométrie, devient Radiomics afin que cette nouvelle identité corresponde davantage à ses projets de développement et ses objectifs de croissance.
- January 4th, 2021
Carlos Meca joins Radiomics as CCO
Radiomics is glad to start the new year 2021 announcing and welcoming its new Chief Commercial Officer (CCO) Carlos Contreras Meca!
- December 30th, 2020
Radiomic CT Signature for Detecting COVID-19
Radiomics developed a fully automated AI framework to extract radiomics features to classify COVID-19 infected patients from standard-of-care medical images (CT).
- November 30th, 2020
Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients
- October 30th, 2020
The DRAGON project: fighting Coronavirus pandemics
The DRAGON project led by Radiomics in partnership with 18 high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient-centred organisations and professional societies from Belgium, Italy, the Netherlands, Switzerland and the UK, has been selected for funding by the Innovative Medicines Initiative (IMI), with an evaluation score placing it in the 95% percentile.
- October 1st, 2020
Mariaelena Occhipinti joins Radiomics as CMO
Radiomics is glad to welcome its new Chief Medical Officer, Mariaelena Occhipinti!